The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.
The gene therapy for an undisclosed central nervous system disease is based on JCR's delivery technology and Modalis' epigenome editing platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback